Compare TNXP & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNXP | FINW |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 194.4M |
| IPO Year | 2008 | 2021 |
| Metric | TNXP | FINW |
|---|---|---|
| Price | $12.79 | $14.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 525.4K | 14.0K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | 21.51 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $558.11 | $160.48 |
| Revenue Next Year | $38.29 | $35.27 |
| P/E Ratio | ★ N/A | $72.75 |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $10.03 | $12.82 |
| 52 Week High | $69.65 | $22.49 |
| Indicator | TNXP | FINW |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 59.52 |
| Support Level | $12.43 | $13.51 |
| Resistance Level | $15.19 | $17.39 |
| Average True Range (ATR) | 1.01 | 0.40 |
| MACD | 0.20 | 0.07 |
| Stochastic Oscillator | 87.20 | 97.11 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.